Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2015

Open Access 01-12-2015 | Primary research

Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma

Authors: Ali Rihani, Jo Vandesompele, Frank Speleman, Tom Van Maerken

Published in: Cancer Cell International | Issue 1/2015

Login to get access

Abstract

Background

Neuroblastoma is a neural crest-derived tumor and is the most common cancer in children less than 1 year of age. We hypothesized that aberrations in genes that control the cell cycle could play an important role in the pathogenesis of neuroblastoma and could provide a tractable therapeutic target.

Methods

In this study, we screened 131 genes involved in cell cycle regulation at different levels by analyzing the effect of siRNA-mediated gene silencing on the proliferation of neuroblastoma cells.

Results

Marked reductions in neuroblastoma cellular proliferation were recorded after knockdown of CCND1 or PLK1. We next showed that pharmacological inhibition of cyclin D1 dependent kinases 4/6 (CDK4/6) with PD 0332991 (palbociclib) reduced the growth of neuroblastoma cell lines, induced G1 cell cycle arrest, and inhibited the cyclin D1-Rb pathway.

Conclusion

Selective inhibition of CDK4/6 using palbociclib may provide a new therapeutic option for treating neuroblastoma.
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
Ackermann S, Goeser F, Schulte JH, Schramm A, Ehemann V, Hero B et al (2011) Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma. Clin Cancer Res 17:731–741PubMedCrossRef
5.
Bell JL, Malyukova A, Kavallaris M, Marshall GM, Cheung BB (2013) TRIM16 inhibits neuroblastoma cell proliferation through cell cycle regulation and dynamic nuclear localization. Cell Cycle 12:889–898PubMedCentralPubMedCrossRef
6.
Creevey L, Ryan J, Harvey H, Bray IM, Meehan M, Khan AR et al (2013) MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1. Mol Cancer 12:23PubMedCentralPubMedCrossRef
7.
Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D et al (2013) Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res 19:6173–6182PubMedCrossRef
8.
Molenaar JJ, van Sluis P, Boon K, Versteeg R, Caron HN (2003) Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma. Genes Chromosom Cancer 36:242–249PubMedCrossRef
9.
Grinshtein N, Datti A, Fujitani M, Uehling D, Prakesch M, Isaac M et al (2011) Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Cancer Res 71:1385–1395PubMedCrossRef
10.
Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E et al (2004) Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3:1427–1438PubMed
11.
Connell-Crowley L, Harper JW, Goodrich DW (1997) Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell 8:287–301PubMedCentralPubMedCrossRef
12.
Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL (2011) Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 11:558–572PubMedCrossRef
13.
Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S et al (2004) Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 279:25549–25561PubMedCrossRef
14.
Ismail IA, Kang K-S, Lee HA, Kim J-W, Sohn Y-K (2007) Genistein-induced neuronal apoptosis and G2/M cell cycle arrest is associated with MDC1 up-regulation and PLK1 down-regulation. Eur J Pharmacol 575:12–20PubMedCrossRef
15.
Molenaar JJ, Ebus ME, Koster J, van Sluis P, van Noesel CJM, Versteeg R et al (2008) Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Res 68:2599–2609PubMedCrossRef
16.
Molenaar JJ, Ebus ME, Koster J, Santo E, Geerts D, Versteeg R et al (2010) Cyclin D1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells. Oncogene 29:2739–2745PubMedCrossRef
17.
Grant GD, Brooks LI, Zhang X, Mahoney JM, Martyanov V, Wood TA et al (2013) Identification of cell cycle-regulated genes periodically expressed in U2OS cells and their regulation by FOXM1 and E2F transcription factors. Mol Biol Cell 24:3634–3650PubMedCentralPubMedCrossRef
18.
Musgrove EA (2006) Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors 24:13–19PubMedCrossRef
19.
Diehl JA, Cheng M, Roussel MF, Sherr CJ (1998) Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12:3499–3511PubMedCentralPubMedCrossRef
20.
Lapenna S, Giordano A (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8:547–566PubMedCrossRef
21.
O’Dwyer PJ, LoRusso P, DeMichele A, Gupta V (2007) A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991. J Clin Oncol 25:3550
22.
23.
Flaherty KT, LoRusso PM, DeMichele A (2012) Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer
24.
Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, Wilner KD et al (2011) Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer 104:1862–1868PubMedCentralPubMedCrossRef
25.
Diab S, Eckhardt S, Tan A, Frenette G, Gore L (2007) A phase I study of R547, a novel, selective inhibitor of cell cycle and transcriptional cyclin dependent kinases (CDKs)—Diab et al. 25 (Suppl 18):3528—ASCO Meeting Abstracts. J Clin Oncol 25:3528
26.
Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M et al (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55:611–622PubMedCrossRef
27.
Rihani A, Van Maerken T, Pattyn F, Van Peer G, Beckers A, De Brouwer S et al (2013) Effective Alu repeat based RT-Qpcr normalization in cancer cell perturbation experiments. PLoS One 8:e71776PubMedCentralPubMedCrossRef
28.
Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J (2007) qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 8:R19PubMedCentralPubMedCrossRef
Metadata
Title
Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma
Authors
Ali Rihani
Jo Vandesompele
Frank Speleman
Tom Van Maerken
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2015
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-015-0224-y

Other articles of this Issue 1/2015

Cancer Cell International 1/2015 Go to the issue

Primary research

Kinetic characterization of lactate dehydrogenase in normal and malignant human breast tissues

Primary research

Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients

Primary research

Stromal-epithelial responses to fractionated radiotherapy in a breast cancer microenvironment

Primary research

Growth inhibitory and chemo-sensitization effects of naringenin, a natural flavanone purified from Thymus vulgaris, on human breast and colorectal cancer

Primary research

RB mutation and RAS overexpression induce resistance to NK cell-mediated cytotoxicity in glioma cells

Primary research

Bioinformatics identification of potentially involved microRNAs in Tibetan with gastric cancer based on microRNA profiling
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits